Dr Robin Hesketh
I am based in the Biochemistry Department and work on several cancer related projects, primarily in collaboration with Jim Metcalfe, Kevin Brindle and Doug Easton. These fall into four areas (1) Development of anti-angiogenic gene therapy, (2) Studies of transforming growth factor beta (TGF?), (3) Studies on a breast cancer-associated gene, TOX3, and (4) Studies of gene expression and metabolomic profiles in response to electromagnetic fields.
Symplectic Elements feed provided by Research Information, University of Cambridge
Griggs, J., Smith, G.A., Brindle, K.M., Metcalfe, J.C. and Hesketh, R. (2002). Inhibition of proliferative retinopathy by the antivascular agent combretastatin-A4. Amer. J. Pathology, 160, 1097-1103. Lücke, C.D., Philpott, A., Metcalfe, J.C., Thompson, A.M., Hughes-Davies, L., Kemp, P.R. and Hesketh, R. (2001). Inhibiting mutations in the transforming growth factor ? type 2 receptor in recurrent human breast cancer. Cancer Research, 61, 482-485. Griggs, J., Hesketh, R., Smith, G.A., Brindle, K.M., Metcalfe, J.C., Thomas, G.A. and Williams, E.D. (2001). Combretastatin-A4 disrupts neo-vascular development in non-neoplastic tissue. British Journal of Cancer, 84, 832-835.